GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Inventories, Inventories Adjustments

KYTX (Kyverna Therapeutics) Inventories, Inventories Adjustments : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Inventories, Inventories Adjustments?

Kyverna Therapeutics's Inventories, Inventories Adjustments for the quarter that ended in Jun. 2024 was $0.00 Mil.


Kyverna Therapeutics Inventories, Inventories Adjustments Historical Data

The historical data trend for Kyverna Therapeutics's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Inventories, Inventories Adjustments Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Inventories, Inventories Adjustments
- - -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only - - - - -

Kyverna Therapeutics Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Kyverna Therapeutics Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics Headlines